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Summary
patients with non-metastatic, stage T3 clear-cell renal cell cancer present a clinical challenge for urologists. The extent 
of tumor thrombus in inferior vena cava is the primary determinant of surgical procedure complexity. level iii and iV 
thrombi require the use of cardiopulmonary bypass and hypothermic arrest. Careful preoperative planning and a multidis-
ciplinary approach are mandatory. in this paper, we report outcomes of 12 patients who were surgically treated in our 
center. The 29 months overall survival for all patients was 69%, while three patients died during follow-up. of nine surviv-
ing patients, six are currently disease-free, whereas three had disease progression. our study showed that carefully selected 
patients with clear-cell renal cell carcinoma with inferior vena cava tumor thrombus level iii and iV could be successfully 
treated with an aggressive surgical approach.
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Clear-cell renal cell carcinoma (ccrCC) ac-
counts for 3.5% of all adult neoplasms and has a 
high mortality rate causing 2.3% of cancer-related 
deaths, making it one of the deadliest urological 
cancers (1). formation of inferior vena cava tumor 
thrombus (iVCTT) can be found in up to 10% of 
patients with ccrCC (2). With no distant metasta-
ses and after successful surgery, these patients 
have a good prognosis with a 5-year overall sur-
vival of 47-63% (3-7). However, if left untreated, 
they have a poor prognosis with a median surviv-
al of 29% and one-year disease-specific survival of 
5 months (8). surgical procedures for the treat-
ment of ccrCC with iVCTT are demanding and 
require careful planning and a multidisciplinary 
approach, but if performed successfully, they give 
patients the best chance of survival. nevertheless, 
it is essential to determine the tumor thrombus 
level in the vena cava before surgery.
The 2017 tumor node metastases (TnM) clas-
sification is inadequate for final decision making 
since it lacks anatomical precision and defines 
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only three levels of thrombus extension: T3a - into 
the renal vein or it is segmental (muscle-contain-
ing) branches, T3b - into the inferior vena cava 
(iVC) below diaphragm and T3c - into iVC above 
the diaphragm or invasion of the caval wall. The 
most widely used classification system of the 
thrombus extension is the Mayo 5-level classifica-
tion: level 0 - into the renal vein only; level i - into 
the iVC but no more than 2 cm above the renal 
vein; level ii - into the iVC 2 cm above the renal 
vein but not to the hepatic vein; level iii - into the 
iVC above the hepatic vein but not to the dia-
phragm; and level iV - into the supradiaphrag-
matic iVC or right atrium (9). levels iii and iV are 
the most challenging and, in most cases, require 
the use of a cardiopulmonary bypass (CpB) with 
deep hypothermic circulatory arrest (DHCa). in-
traoperative and postoperative complications 
such as myocardial infarction, cerebrovascular ac-
cident, congestive heart failure, pulmonary embo-
lism, atelectasis, pneumonia, and thrombophlebi-
tis occur in up to 30% of cases, and the 90-day 
mortality rate is 3-16% (10, 11).
This paper aims to present our experience in 
treating ccrCC with level iii and iV inferior vena 
cava tumor thrombi.
MATERIALS AND METHODS
in this single-center retrospective observa-
tional study, we analyzed archived patient’s med-
ical records. We report the demographic data, sur-
Figure 1. Large tumor thrombus in inferior vena cava on com-
puterized tomography Figure 2. Kidney with tumor and visible large tumor thrombus
gical procedures, intraoperative and postopera-
tive complications, final histological diagnosis, 
and overall survival using descriptive statistics. 
all patients underwent a thorough preoperative 
diagnostic workup. radiologic staging and the 
determination of the upper extent of tumor throm-
bus in iVC was performed by contrast-enhanced 
computed tomography and/or magnetic reso-
nance imaging (figure 1). When indicated, echo-
cardiography was performed to detect a thrombus 
extension in the right atrium.
The patients were presented on a multidisci-
plinary tumor board consisting of urologists, on-
cologists, radiologists, anesthesiologists, and car-
diothoracic surgeons to determine the optimal in-
dividual treatment option. all patients signed 
informed consent.
Surgical approach
The operation can be divided into two parts, 
urological and cardiothoracic. first, a Chevron in-
cision is made, and the colon mobilized, followed 
by detailed identification and preparation of all 
relevant anatomical structures. The renal artery 
should be ligated as soon as possible, while the 
right and the left renal vein and iVC should be ex-
posed. Careful intraoperative assessment of 
thrombus extension is mandatory. once all the 
veins have been prepared and secured for vascu-
lar control, the cardiothoracic part begins with a 
median sternotomy for the approach to the heart. 
The extracorporeal bypass is established, and hy-
pothermia of 18°C induced, after which the car-
diopulmonary arrest occurs. The cardiothoracic 
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surgeon’s role is also to determine the supradia-
phragmatic extent of the tumor thrombus and, 
when indicated, open the right atrium and assist 
in removing the thrombus by mobilizing it cau-
dally. as the urological part of the procedure re-
sumes, an iVC incision is made, and the tumor 
thrombus is extracted, the iVC is sutured, and the 
kidney with the tumor is removed, followed by 
heart rewarming and gaining spontaneous sinus 
rhythm after which the bypass is removed (fig-
ures 2-3). The procedure ends with the placement 
of drainage and closure of the wounds.
RESULTS
Twelve patients with ccrCC and iVCTT were 
surgically treated from april 2011 to february 
2020 in our center. patients and tumor characteris-
tics are shown in Table 1. preoperatively, iVC tu-
mor thrombus was classified as level III or level 
iV. Therefore all procedures were performed in 
collaboration with cardiothoracic surgeons. elev-
en procedures included CpB with DHCa, and one 
procedure was performed without bypass be-
cause, after sternotomy, pericardiotomy, inspec-
tion, and palpation of the right atrium, the throm-
bus was not evident supradiafragmatically, so the 
procedure was completed only by abdominal ap-
proach.
There were no intraoperative or 90-day peri-
operative deaths. none of the patients had Cla-
vien Dindo grade iii or higher postoperative com-
plications. four Clavien Dindo grade ii complica-
tions occurred: two patients had atrial fibrillation, 
one patient had a pneumothorax and atrial fibril-
lation, and one patient had transitory lower limb 
ischemia. all these complications were managed 
conservatively. The median follow-up was 38 
months (iQ range 16.75 - 66 months). Three pa-
tients died during follow up, two due to cardio-
vascular comorbidity and one due to disease pro-
gression. The 29 months overall survival for all 
patients was 69% (figure 4). nine surviving pa-
tients undergo regular oncological follow-up. six 
are disease-free, whereas three had disease pro-
gression, two are receiving first-line systematic 
treatment for pulmonary metastases (sunitinib 
and nivolumab), and one is on the second-line for 
hepatic metastases (nivolumab + axitinib). in our 
series, three patients had 5-years disease-free, and 
seven patients had 2-years disease-free survival.
DISCUSSION
our study showed that patients with stage 
T3 ccrCC and iVCTT levels iii and iV can be suc-
cessfully treated with an aggressive surgical ap-
Figure 3. Kidney with tumor and large tumor thrombus after 
nephrectomy
Table 1.





Left side 4 (33,3%)
Right side 8 (66,7%)
Median (IQ range)
Age (years) 63,5 (54,5-70,25)
Preoperative Mayo Classification Number (Percentage)
Level III 4 (33,3%)
Level IV 8 (66,7%)
Figure 4. Overall survival curve for all operated patients
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proach. Although these patients pose a significant 
challenge for surgeons, anesthesiologists, and all 
the other surgical team members, radical and 
complete removal of the tumor and tumor throm-
bus seems to be the most important determinant 
of curative treatment. This demanding surgery 
has a high rate of severe perioperative and postop-
erative complications in up to 30% of cases. pa-
tients with supradiaphragmatic iVCTT have 11-
fold higher postoperative complication rates when 
compared to patients with renal vein involvement 
only, with intraoperative bleeding and postopera-
tive arrhythmias and secondary hemorrhage be-
ing the most common (10). Cardiopulmonary by-
pass with the deep hypothermic circulatory arrest 
was introduced in 1984 as a new method for the 
management of ccrCC with supradiaphragmatic 
IVCTT (14). Although incredibly beneficial for 
iVCTT surgery, the use of CpB and DHCa can 
produce platelet dysfunction and coagulopathy, 
thus facilitating bleeding in the postoperative pe-
riod (15).
In our series, we had no significant intraop-
erative complications, and all postoperative com-
plications were treated conservatively. although 
we did not have intraoperative or perioperative 
mortality, the previously reported series showed a 
3-16% mortality (9-13).
The association between the level of proximal 
venous thrombus and overall survival is still un-
clear. some studies showed no association, while 
others identified IVC involvement as a negative 
prognostic factor (11). However, atrial involve-
ment with tumor thrombus adds complexity to 
the procedure, increasing the probability of intra-
operative morbidity and mortality. since this type 
of surgery has considerable risks, the patient and 
his family must be informed about possible com-
plications and adverse outcomes. Due to the com-
plexity of cases with thrombus going from renal 
vein to right atrium, careful preoperative plan-
ning and a multidisciplinary approach are man-
datory.
The use of optimal surgical techniques and 
collaboration between urologists, abdominal and 
cardiothoracic surgeons, radiologists, oncologists, 
and anesthesiologists is needed to achieve the best 
oncological results without risking the patient’s 
safety.
level i and ii iVCTT can be managed with 
the iVC occlusion and can be resected without by-
pass. for level iii and iV thrombus, liver mobiliza-
tion and dissection of iVC and the use of CpB and 
DHCa are usually needed for the complete re-
moval of tumor thrombus and vascular stability of 
the patient. since all of our patients had level iii 
and iV iVCTT, we needed a cardiothoracic sur-
geon’s support.
With advances in minimally invasive sur-
gery, laparoscopic and robotic nephrectomy with 
thrombectomy were proven feasible and safe for 
carefully selected patients in experienced centers 
(10,16). Wang et al. reported a series of 13 patients 
with level iii and iV tumor thrombi that have been 
performed successfully using a combination of ro-
botic surgery, thoracoscopy-assisted thrombecto-
my, and CpB (16). Currently, there is an active 
phase iii study investigating neoadjuvant thera-
py’s potential effect with nivolumab for patients 
with high-risk, non-metastatic rCC (17). The 
prosper study’s primary goal is to improve re-
currence-free survival, but it would be interesting 
to evaluate the impact of neoadjuvant therapy in 
the reduction of tumor thrombus, thus facilitating 
the surgical procedure.
in conclusion, surgical treatment of advanced 
ccrCC involving the iVC is feasible with accept-
able morbidity and mortality in carefully selected 
patients. This procedure should be performed in 
experienced centers and with a multidisciplinary 
surgical approach. long-term survival can be 
achieved for patients without proven metastases.
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Sažetak
MULTIDISCIPLINARNO KIRURŠKO LIJEČENJE BUBREŽNOG KARCINOMA SVIJETLIH STANICA  
SA TUMORSKIM TROMBOM DONJE ŠUPLJE VENE RAZINE III I IV: NAŠE ISKUSTVO U PROTEKLOM DESETLJEĆU
T. Hudolin, V. Ferenčak, L. Penezić, T. Zekulić, T. Kuliš, M. Marić, O. Pavlović, A. El-Saleh,  
N. Knežević, E. Goluža, B. Biočina i Ž. Kaštelan
Pacijenti sa nemetastatskim, svijetlostaničnim karcinomom bubrega stadija T3, predstavljaju klinički izazov za urolo-
ge. Doseg tumorskog tromba unutar donje šuplje vene je glavna odrednica složenosti krurškog zahvata. Tumorski trombi 
razine III i IV zahtijevaju upotrebu kardiopulmonalnog premoštenja I hipotermijskog aresta. Pažljiva preoperativna procje-
na i multidisciplinarni pristup je neophodan. U našem centru je liječeno 12 pacijenata sa svijetlostaničnim karcinomom bu-
brega i tumorskim trombom u donjoj šupljoj veni. Ukupno preživljenje nakon 29 mjeseci je za ove pacijente bilo 69%. U 
ovom trenutku, od 9 preživjelih pacijenata, 6 je bez recidiva bolesti, a 3 imaju progresiju. U našoj studiji smo pokazali da 
pažljivo izabrani pacijenti sa svijetlostaničnim karcinomom bubrega i tumorskim trombom razine III i IV mogu biti izliječe-
ni agresivnim kirurškim pristupom.
KLJUČNE RIJEČI: karcinom bubrežnih stanica, donja šuplja vena, venska tromboza, radikalna nefrektomija, izvantjelesna cirkulacija
